Showing 5651-5660 of 6035 results for "".
- Clinical Study Showing Reduced Incidence of Cystoid Macular Edema with Omidria Presented at ASCRShttps://modernod.com/news/clinical-study-showing-reduced-incidence-of-cystoid-macular-edema-with-omidria-presented-at-ascrs/2476575/Omeros announced the results of a real-world clinical study showing that its FDA-approved ophthalmic drug Omidria (phenylephrine and ketorolac intraocular solution) 1% / 0.3% decreases the incidence of postoperative cystoid macular edema (CME), a sight-threatening complication of cataract surgery
- Drusen Characteristics Linked With AMD Risk in Fellow Eyeshttps://modernod.com/news/drusen-characteristics-linked-with-amd-risk-in-fellow-eyes/2476571/In patients with unilateral neovascular age-related macular degeneration (AMD), certain drusen features are associated with conversion to neovascular AMD in the fellow eye, according to a secondary analysis of data from a clinical trial, as re
- Noveome Biotherapeutics Announces Publication of Further Preclinical Results Supporting the Neuroprotective Properties of ST266 in Retinal Ganglion Cellshttps://modernod.com/news/noveome-biotherapeutics-announces-publication-of-further-preclinical-results-supporting-the-neuroprotective-properties-of-st266-in-retinal-ganglion-cells/2476572/Noveome Biotherapeutics announced the publication of preclinical results for ST266, its proprietary, cell-free platform biologic, published in the Journal of Neuro-Ophthalmology. These new results further support the neuroprotective properties of intranasally delivered ST266 in mice with e
- Cholesterol-Lowering Drugs Tied to Reduced Glaucoma Riskhttps://modernod.com/news/cholesterol-lowering-drugs-tied-to-reduced-glaucoma-risk/2476570/High cholesterol is associated with an increased risk of developing glaucoma, but a new study suggests taking statins to lower cholesterol helps to reduce this risk, according to a Reuters
- InstruSafe by Summit Medical Introduces New InstruSafe XL Transport Containerhttps://modernod.com/news/instrusafe-by-summit-medical-introduces-new-instrusafe-xl-transport-container/2476565/InstruSafe by Summit Medical has introduced the new InstruSafe XL Transport Container—the first and only container of its size on the market—designed to accommodate da Vinci SP, Xi Scopes, EndoWrist and other long laparoscopic surgical instruments, according to a company news release. The XL Tra
- Pentosan Polysulfate Sodium Treatment Strongly Linked With Maculopathy and Vision Losshttps://modernod.com/news/pentosan-polysulfate-sodium-treatment-strongly-linked-with-maculopathy-and-vision-loss/2476563/Patients taking pentosan polysulfate sodium (PPS), which has been on the market for many years, appear to be at greater risk for a newly described maculopathy and vision loss, researchers report, according to Reuters. “Exposu
- Oxurion Issues Financial and Business Updatehttps://modernod.com/news/oxurion-issues-financial-and-business-update/2476562/Oxurion NV issued a business and a financial update for the 3 months ending March 31, 2019. Oxurion is developing a competitive pipeline of disease modifying drug candidates for diabetic eye disease, particularly DME. The Oxurion clinical development pipeline consists of novel products wit
- Mati Therapeutics Phase 2 Nepafenac Evolute Clinical Trial Results Show Significant Postoperative Pain Reductionhttps://modernod.com/news/mati-therapeutics-phase-2-nepafenac-evolute-clinical-trial-results-show-significant-postoperative-pain-reduction/2476558/Mati Therapeutics announced that it has completed a phase 2 clinical trial evaluating the safety and efficacy of nepafenac delivered in Mati’s proprietary Evolute sustained ocular punctal plug drug delivery platform. The trial was a multicenter, randomized, masked evaluation of Nepafenac Evolute
- Alcon Launches Advancements to the Centurion Vision System at ASCRShttps://modernod.com/news/alcon-launches-advancements-to-the-centurion-vision-system-at-ascrs/2476556/Alcon introduced new phaco technology that is part of the Centurion Vision System, including the Active Sentry Handpiece and Intrepid Hybrid Tip, at the ASCRS annual meeting. These new products, which are designed to improve safety, consistency and control during cataract surgery,
- Nicox Presents First Data on New Class of Nitric Oxide (NO)-Donating Compounds for Glaucoma at ARVOhttps://modernod.com/news/nicox-presents-first-data-on-new-class-of-nitric-oxide-no-donating-compounds-for-glaucoma-at-arvo/2476545/Nicox SA announced that it has presented the first data from a new drug class designed to lower IOP (NO-donating PDE5 inhibitors) at a poster presentation during the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The first